CARTITUDE-4 — Ciltacabtagene Autoleucel Versus Standard Care in Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)

Phase 3 · 2023 · Multiple Myeloma

Design

Randomized trial of ciltacabtagene autoleucel versus standard care (pomalidomide-bortezomib-dexamethasone or daratumumab-pomalidomide-dexamethasone).

Population

Lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy.

Primary Endpoint

progression-free survival (PFS)

Key Result

PFS markedly improved (HR 0.26); 12-month PFS 76% vs 49% favoring cilta-cel over standard care.

Guideline Impact

NCCN-listed ciltacabtagene autoleucel for lenalidomide-refractory multiple myeloma after 1-3 prior lines